Retinalamin / Cortexin: local ocular delivery method — RU2195297C2
И.Б. Максимов, В.Х. Хавинсон, Л.К. Мошетова, Г.В. Анисимова · 2002 · RU2195297C2 · patent family 20229433
Published 2002-12-27.
Reported patent results
Reported findings
The patent reports visual gains and persistence over follow-up, with two advanced-disease eyes showing no objective benefit.
Uncontrolled patent report of 65 patients (80 eyes), aged 18–80, receiving local delivery of retina- or cortex-derived preparations.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Visual acuity and fields | Acuity increases of 0.01–0.4 and field expansion averaging 10–15° reported | Before/after; not an untreated comparison · 1 week |
| Additional acuity and field changes | Acuity increased a further 0.05–0.2; fields expanded a further 5–10° | Relative to the preceding examination, as described · 1 month |
| Persistence and non-response | Results described as stable at 3 and 6 months; no objective positive effect in two advanced-disease eyes | Follow-up duration varied from 1 to 6 months |
| Reported tolerability | No allergic or adverse effects reported | Uncontrolled reporting does not establish safety of invasive delivery |
Heterogeneous diagnoses, non-independent eyes and absence of a concurrent control prevent causal inference. Results cannot be assigned to both extracts as if each had been independently tested.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The patent describes a surgical delivery method involving retina- or brain-cortex-derived peptide preparations; the description identifies Retinalamin and Cortexin.
This is a delivery-method disclosure, not proof of safety or superiority of an invasive route. It must not be counted as independent clinical replication without checking related reports.
- Publication
- RU2195297C2 ↗ · 2002-12-27
- Earliest priority / filing
- 2000-01-20 / 2000-01-20
- Original applicant / assignee
- Общество с ограниченной ответственностью "Клиника Института биорегуляции и геронтологии"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20229433 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method for treating dystrophic diseases of eyes
Inventors: И.Б. Максимов; В.Х. Хавинсон; Л.К. Мошетова; Г.В. Анисимова.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- This is a delivery-method disclosure, not proof of safety or superiority of an invasive route. It must not be counted as independent clinical replication without checking related reports.
- Heterogeneous diagnoses, non-independent eyes and absence of a concurrent control prevent causal inference. Results cannot be assigned to both extracts as if each had been independently tested.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-20229433. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: И.Б. Максимов, В.Х. Хавинсон, Л.К. Мошетова, Г.В. Анисимова. Retinalamin / Cortexin: local ocular delivery method — RU2195297C2 RU2195297C2 · patent family 20229433 2002.
Molekul research summary: https://molekul.io/research/patent-ru2195297c2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Retinalamin
A retinal tissue-derived peptide preparation studied in ophthalmology. It is distinct from the short-peptide catalogue entry Normophthal.
Cortexin
A tissue-derived preparation with Russian stroke, cognitive, pediatric and other clinical reports. Study designs vary; the independent stroke review is shown alongside favorable original reports. None validates the personal WHOOP diary.